Yazar "Yucel, Birsen" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer
    (Galenos Yayincilik, 2016) Hasbek, Zekiye; Dogan, Omer Tamer; San, Ismail; Yucel, Birsen; Seker, Mehmet Metin; Turgut, Bulent; Berk, Serdar
    Objective: Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUVmax), SUVave, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size. Methods: Serum anti-p53 Ab level was studied in three groups. Patients who underwent F-18-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent F-18-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN= pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers. Results: Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p< 0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUVmax, SUVave, TLG, tumor volume and tumor size of patients with lung cancer (p> 0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p> 0.05). Conclusion: It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion.
  • Küçük Resim Yok
    Öğe
    The Prognostic Value of High Pretreatment Plasma D-Dimer Levels in Non-Metastatic Breast Cancer Patients with Absence of Venous Thromboembolism
    (Akad Doktorlar Yayinevi, 2016) Kacan, Turgut; Yucel, Birsen; Bahar, Seher; Celasun, Gurol; Seker, Mehmet M.; Babacan, Nalan; Bahceci, Aykut
    Systemic activation of coagulation and fibrinolysis is frequently observed in cancer patients without thrombosis. Recent studies have showed the association between D-Dimer (DD) and metastatic spread and prognosis of cancer. We aimed to investigate the prognostic value of DD in patients with non metestatic breast cancer (nMBC) and evaluated the DD levels and other variables for overall survival (OS) using univariate and multivariate analyses in 448 patients. The median follow-up time was 50 months (3-151 months). There was only significant relationship between DD and distant metastases (p=0.052). Performance status (PS) (p<0.001 and < 0.001), stage (p<0.001 and < 0.001), CEA (p<0.001 and < 0.001), CA 15-3 (p<0.001 and < 0.001) and DD (p<0.001 and 0.034) were determined as prognostic factors for OS in univariate analysis. In multivariate analysis, PS (ECOG 0 vs ECOG 1, p=0.022; ECOG 0 vs ECOG >= 2, (p<0.001), stage (stage I vs stage II, p=0.566; stage I vs stage III, p=0.033), the CA 15-3 (p=0.048) and DD levels (p=0.015) were determined as independent prognostic factors for OS. In conclusion, pretreatment high DD level is an important prognostic factor in patients with non metastatic breast cancer and high DD levels were associated with poor outcome.